A Phase Ib Study of Sorafenib (BAY 43‐9006) in Patients with Kaposi Sarcoma

LESSONS LEARNED. Oral targeted agents are desirable for treatment of Kaposi sarcoma (KS); however, in patients with HIV, drug–drug interactions must be considered. In this study to treat KS, sorafenib was poorly tolerated at doses less than those approved by the U.S. Food and Drug Administration for...

Descripción completa

Detalles Bibliográficos
Autores principales: Uldrick, Thomas S., Gonçalves, Priscila H., Wyvill, Kathleen M., Peer, Cody J., Bernstein, Wendy, Aleman, Karen, Polizzotto, Mark N., Venzon, David, Steinberg, Seth M., Marshall, Vickie, Whitby, Denise, Little, Richard F., Wright, John J., Rudek, Michelle A., Figg, William D., Yarchoan, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423501/
https://www.ncbi.nlm.nih.gov/pubmed/28341759
http://dx.doi.org/10.1634/theoncologist.2016-0486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423501/
https://www.ncbi.nlm.nih.gov/pubmed/28341759
http://dx.doi.org/10.1634/theoncologist.2016-0486

Ejemplares similares